{"created":"2023-06-26T11:01:38.953899+00:00","id":2399,"links":{},"metadata":{"_buckets":{"deposit":"dbab1d08-ad71-48ac-84be-3cd66c042f34"},"_deposit":{"created_by":31,"id":"2399","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"2399"},"status":"published"},"_oai":{"id":"oai:oist.repo.nii.ac.jp:00002399","sets":["6:213"]},"author_link":["15921","15914","15916","15917","15919","15913","15915","15920","15918"],"item_10001_biblio_info_7":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11-24","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"12","bibliographicPageStart":"3291","bibliographicVolumeNumber":"10","bibliographic_titles":[{},{"bibliographic_title":"Cells","bibliographic_titleLang":"en"}]}]},"item_10001_creator_3":{"attribute_name":"Author","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Dewanjee, Saikat"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kandimalla, Ramesh"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kalra, Rajkumar Singh"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Valupadas, Chandrasekhar"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Vallamkondu, Jayalakshmi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kolli, Viswakalyan"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Dey Ray, Sarbani"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Reddy, Arubala P."}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Reddy, P. Hemachandra"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"Abstract","attribute_value_mlt":[{"subitem_description":"Hyperactivation of immune responses resulting in excessive release of pro-inflammatory mediators in alveoli/lung structures is the principal pathological feature of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The cytokine hyperactivation in COVID-19 appears to be similar to those seen in rheumatoid arthritis (RA), an autoimmune disease. Emerging evidence conferred the severity and risk of COVID-19 to RA patients. Amid the evidence of musculoskeletal manifestations involving immune-inflammation-dependent mechanisms and cases of arthralgia and/or myalgia in COVID-19, crosstalk between COVID-19 and RA is often debated. The present article sheds light on the pathological crosstalk between COVID-19 and RA, the risk of RA patients in acquiring SARS-CoV-2 infection, and the aspects of SARS-CoV-2 infection in RA development. We also conferred whether RA can exacerbate COVID-19 outcomes based on available clinical readouts. The mechanistic overlapping in immune-inflammatory features in both COVID-19 and RA was discussed. We showed the emerging links of angiotensin-converting enzyme (ACE)-dependent and macrophage-mediated pathways in both diseases. Moreover, a detailed review of immediate challenges and key recommendations for anti-rheumatic drugs in the COVID-19 setting was presented for better clinical monitoring and management of RA patients. Taken together, the present article summarizes available knowledge on the emerging COVID-19 and RA crosstalk and their mechanistic overlaps, challenges, and therapeutic options.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"info:doi/10.3390/cells10123291","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"Related site","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.mdpi.com/2073-4409/10/12/3291/htm","subitem_relation_type_select":"URI"}}]},"item_10001_rights_15":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2021 The Author(s)"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2073-4409","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"Author's flag","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-12-01"}],"displaytype":"detail","filename":"cells-10-03291_a.pdf","filesize":[{"value":"2.8 MB"}],"format":"application/pdf","license_note":"CC BY 4.0\nCreative Commons Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0/)","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"cells-10-03291_a","url":"https://oist.repo.nii.ac.jp/record/2399/files/cells-10-03291_a.pdf"},"version_id":"4e789254-4ad3-4823-a51c-cbab6e4373fd"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ACE","subitem_subject_scheme":"Other"},{"subitem_subject":"ACE2","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-rheumatic drugs","subitem_subject_scheme":"Other"},{"subitem_subject":"COVID-19","subitem_subject_scheme":"Other"},{"subitem_subject":"cytokine storm","subitem_subject_scheme":"Other"},{"subitem_subject":"immune response","subitem_subject_scheme":"Other"},{"subitem_subject":"inflammation","subitem_subject_scheme":"Other"},{"subitem_subject":"rheumatoid arthritis","subitem_subject_scheme":"Other"},{"subitem_subject":"SARS-CoV-2","subitem_subject_scheme":"Other"},{"subitem_subject":"therapeutic options","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"31","path":["213"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-01"},"publish_date":"2021-12-01","publish_status":"0","recid":"2399","relation_version_is_last":true,"title":["COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges"],"weko_creator_id":"31","weko_shared_id":31},"updated":"2023-06-26T11:31:30.329202+00:00"}